Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation

✍ Scribed by Qingcai Wang; Dimitris Horiatis; Jacek Pinski

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: French
• Weight: 701 KB
• Volume: 111
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.20286

✦ Synopsis

Abstract

In vitro, the human prostate cancer (PCA) cell line LNCaP can be permanently transdifferentiated into a quiescent neuroendocrine (NE) phenotype by the cytokine interleukin‐6 (IL‐6). Recently, we have shown that the growth of prostate cancer cells is significantly suppressed when cocultured with NE cells. In order to explore the inhibitory activity of IL‐6 on prostate tumor growth, nude mice bearing xenografts of the PCA cell lines LNCaP and DU‐145 (a line that is incapable of NE transdifferentiation by IL‐6 in vitro) were treated with IL‐6 for 3 weeks, either injected around the tumor or systematically released from implanted minipumps. Both administration forms of IL‐6 inhibited the growth of LNCaP xenografts by more than 75% compared to the control group. In contrast, there was no difference in DU‐145 tumor growth between IL‐6‐treated animals and controls. In comparison to control and DU‐145 tumors, both IL‐6 injected and pump‐infused LNCaP tumors exhibited a significant increase in the expression of the NE markers neuron‐specific enolase (NSE) and βIII tubulin. Serum NSE levels were also significantly elevated in both IL‐6‐treated LNCaP tumor groups when compared to controls. IL‐6 treatment resulted in G~0~ cell cycle accumulation as evidenced by a loss of Ki‐67 expression in > 90% of LNCaP tumor cells. These combined results demonstrate that IL‐6‐induced NE transdifferentiation of PCA cells has a significant inhibitory effect on tumor growth in mice. Agents, like IL‐6, capable of NE transdifferentiation of PCA cells, should be considered as a new therapeutic approach for the treatment of prostate cancer. © 2004 Wiley‐Liss, Inc.